SCHEMBL31401660

SCHEMBL31401660

O=C(O)c1cccc(S(=O)(=O)C(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 3/20 0.53
▸ PRSS1 P07477 3/20 0.53
▸ PRSS2 P07478 3/20 0.53
▸ PRSS3 P35030 3/20 0.53
▸ CA1 P00915 2/20 0.53
▸ CA2 P00918 2/20 0.53
▸ MAPT P10636 1/20 0.51
▸ IL1RN P18510 1/20 0.51
▸ CYP2C19 P33261 1/20 0.50
▸ AKR1C3 P42330 4/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ AKR1C1 Q04828 1/20 0.49
▸ MEP1B Q16820 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ PTK2B Q14289 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401034 1.00 F2 (0.53) F2PRSS1PRSS2PRSS3CA1
SCHEMBL31400805 0.84 GAA (0.51) F2PRSS1PRSS2PRSS3CA1
SCHEMBL31401289 0.83 F2 (0.50) F2PRSS1PRSS2PRSS3CA1
SCHEMBL31401325 0.83 F2 (0.50) F2PRSS1PRSS2PRSS3CA1
SCHEMBL31401157 0.83 F2 (0.50) F2PRSS1PRSS2PRSS3CA1
SCHEMBL29971360 0.82 F2 (0.53) F2PRSS1PRSS2PRSS3CA1
SCHEMBL4248336 0.82 F2 (0.53) F2PRSS1PRSS2PRSS3CA1
SCHEMBL24017473 0.81 LCK (0.52) F2PRSS1PRSS2PRSS3CA1
SCHEMBL1436244 0.79 F2 (0.57) F2PRSS1PRSS2PRSS3CA1
SCHEMBL30901134 0.79 F2 (0.57) F2PRSS1PRSS2PRSS3CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
Send feedback